Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR440340 dose-ranging study in moderate-to-severe asthma
2019-003751-10Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing SAR440340 dose-ranging arms with Placebo (2 arms). Primary endpoints: Absolute change from baseline in FEV1 (prebronchodilator) and Absolute change from baseline in FEV1 (prebronchodilator) in eosinophil-high subgroup. Started Mar 2020; status: terminated.
02
Drugs
itepekimab
03
Conditions
asthma
Beyond the preview
Go deeper on 2019-003751-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003751-10.